Pure Global: USA MedTech Cybersecurity & Its Hidden Deal Killers

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Add to cart failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

Pure Global: USA MedTech Cybersecurity & Its Hidden Deal Killers

Listen for free

View show details

About this listen

The FDA's new cybersecurity rules are more than just a regulatory checklist; they're reshaping the landscape for MedTech investment and acquisitions. Many innovative startups are discovering that their market access and company valuation now hinge entirely on their cybersecurity preparedness, an area they may have overlooked. This episode of MedTech Global Insights explores the immediate business impact of these stringent new requirements. We uncover why a lack of cybersecurity documentation is becoming a common reason for the FDA to reject new device submissions and, more critically, why it's becoming a deal-breaker in high-stakes M&A negotiations. A fast-growing startup with a breakthrough cardiac monitoring device was in the final stages of a major acquisition. The deal collapsed unexpectedly. The reason was not the device's clinical performance, but its failure to produce a complete Software Bill of Materials (SBOM) as required by the new FDA cybersecurity guidance. The acquiring company's due diligence team flagged it as a critical liability, making the deal too risky to proceed. 本期干货: - What are the three non-negotiable items the FDA now demands in every cybersecurity submission? - Why is an incomplete Software Bill of Materials (SBOM) becoming a primary red flag for investors? - How can early-stage startups implement a compliant Secure Product Development Framework without a large budget? - What specific documentation are acquiring companies demanding during M&A due diligence? - How do the new US cybersecurity rules affect devices that are also seeking CE marking in Europe? - Is your current regulatory strategy robust enough to pass both an FDA review and a buyer's scrutiny? - What are the hidden costs of remediating a device that was not designed with cybersecurity in mind from day one? For more insights, contact us at info@pureglobal.com or visit https://pureglobal.com/. For free AI tools and a comprehensive medical device database, check out https://pureglobal.ai/.

No reviews yet